Premium
Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents
Author(s) -
Othman Tamer A.,
Mei Matthew,
Zhang Jianying,
Aldoss Ibrahim,
Stein Anthony,
Forman Stephen J.,
Marcucci Guido,
Pullarkat Vinod
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26117
Subject(s) - venetoclax , thrombocytosis , medicine , hypomethylating agent , oncology , azacitidine , leukemia , platelet , chronic lymphocytic leukemia , biology , gene , genetics , gene expression , dna methylation
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom